Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

Similar articles for PubMed (Select 23760064)


Schistosomiasis and impaired response to antiretroviral therapy among HIV-infected patients in Tanzania.

Efraim L, Peck RN, Kalluvya SE, Kabangila R, Mazigo HD, Mpondo B, Bang H, Todd J, Fitzgerald DW, Downs JA.

J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):e153-6. doi: 10.1097/QAI.0b013e318282a1a4. No abstract available.


Association between CD4+ T-lymphocyte counts and fecal excretion of Schistosoma mansoni eggs in patients coinfected with S. mansoni and human immunodeficiency virus before and after initiation of antiretroviral therapy.

Muok EM, Simiyu EW, Ochola EA, Ng'ang'a ZW, Secor WE, Karanja DM, Mwinzi PN.

Am J Trop Med Hyg. 2013 Jul;89(1):42-5. doi: 10.4269/ajtmh.13-0045. Epub 2013 May 13.


Schistosomiasis and HIV-1 infection in rural Zimbabwe: implications of coinfection for excretion of eggs.

Kallestrup P, Zinyama R, Gomo E, Butterworth AE, van Dam GJ, Erikstrup C, Ullum H.

J Infect Dis. 2005 Apr 15;191(8):1311-20. Epub 2005 Mar 9.


Schistosomiasis and HIV in rural Zimbabwe: efficacy of treatment of schistosomiasis in individuals with HIV coinfection.

Kallestrup P, Zinyama R, Gomo E, Butterworth AE, van Dam GJ, Gerstoft J, Erikstrup C, Ullum H.

Clin Infect Dis. 2006 Jun 15;42(12):1781-9. Epub 2006 May 10.


Predictors of change in CD4 lymphocyte count and weight among HIV infected patients on anti-retroviral treatment in Ethiopia: a retrospective longitudinal study.

Reda AA, Biadgilign S, Deribew A, Gebre B, Deribe K.

PLoS One. 2013;8(4):e58595. doi: 10.1371/journal.pone.0058595. Epub 2013 Apr 3.


Gender differences in HIV disease progression and treatment outcomes among HIV patients one year after starting antiretroviral treatment (ART) in Dar es Salaam, Tanzania.

Mosha F, Muchunguzi V, Matee M, Sangeda RZ, Vercauteren J, Nsubuga P, Lyamuya E, Vandamme AM.

BMC Public Health. 2013 Jan 15;13:38. doi: 10.1186/1471-2458-13-38.


Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings.

Marazzi MC, Liotta G, Germano P, Guidotti G, Altan AD, Ceffa S, Lio MM, Nielsen-Saines K, Palombi L.

AIDS Res Hum Retroviruses. 2008 Apr;24(4):555-60. doi: 10.1089/aid.2007.0217.


Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in the Netherlands.

Nellen JF, Wit FW, De Wolf F, Jurriaans S, Lange JM, Prins JM.

J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):943-50.


Prevalence of opportunistic intestinal parasitic infections among HIV-infected patients with low CD4 cells counts in France in the combination antiretroviral therapy era.

Pavie J, Menotti J, Porcher R, Donay JL, Gallien S, Sarfati C, Derouin F, Molina JM.

Int J Infect Dis. 2012 Sep;16(9):e677-9. doi: 10.1016/j.ijid.2012.05.1022. Epub 2012 Jul 6.


CD4 cell count recovery in HIV/TB co-infected patients versus TB uninfected HIV patients.

Wanchu A, Kuttiatt VS, Sharma A, Singh S, Varma S.

Indian J Pathol Microbiol. 2010 Oct-Dec;53(4):745-9. doi: 10.4103/0377-4929.72070.


Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study.

Wandeler G, Gsponer T, Bihl F, Bernasconi E, Cavassini M, Kovari H, Schmid P, Battegay M, Calmy A, Egger M, Furrer H, Rauch A; Swiss HIV Cohort Study.

J Infect Dis. 2013 Nov 1;208(9):1454-8. doi: 10.1093/infdis/jit351. Epub 2013 Jul 30.


Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.

Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M; Swiss HIV Cohort Study.

Clin Infect Dis. 2005 Aug 1;41(3):361-72. Epub 2005 Jun 24.


Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.

Mbougua JB, Laurent C, Kouanfack C, Bourgeois A, Ciaffi L, Calmy A, Gwet H, Koulla-Shiro S, Ducos J, Mpoudi-Ngolé E, Molinari N, Delaporte E.

BMC Public Health. 2010 Mar 1;10:105. doi: 10.1186/1471-2458-10-105.


Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition.

Cingolani A, Cozzi Lepri A, Castagna A, Goletti D, De Luca A, Scarpellini P, Fanti I, Antinori A, d'Arminio Monforte A, Girardi E.

Clin Infect Dis. 2012 Mar;54(6):853-61. doi: 10.1093/cid/cir900. Epub 2011 Dec 12.


Impaired CD4+ cell recovery during antiretroviral therapy in patients with HIV resistance mutations.

Sühs KW, Stoll M, Diem R, Schmidt RE, Heiken H.

Arch Virol. 2012 Mar;157(3):433-40. doi: 10.1007/s00705-011-1191-9. Epub 2011 Dec 18.


Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.

Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD; HepaI.Co.N.A. Study Group; Italian Cohort Naive for Antiretrovirals Study Group.

Clin Infect Dis. 2005 Jun 15;40(12):e101-9. Epub 2005 May 5.


Prognostic factors of combined viral load and CD4+ cell count responses under triple antiretroviral therapy, Aquitaine cohort, 1996-1998.

Marimoutou C, Chêne G, Mercié P, Neau D, Farbos S, Morlat P, Ceccaldi J, Dabis F; Groupe d'Epidemiologie Clinique du SIDA en Aquitaine.

J Acquir Immune Defic Syndr. 2001 Jun 1;27(2):161-7.


Vitamin D and HIV progression among Tanzanian adults initiating antiretroviral therapy.

Sudfeld CR, Wang M, Aboud S, Giovannucci EL, Mugusi FM, Fawzi WW.

PLoS One. 2012;7(6):e40036. doi: 10.1371/journal.pone.0040036. Epub 2012 Jun 29.


Antiretroviral therapy in HIV-infected individuals in clinical practice: are the criteria for initiating and choosing the type of drug regimen based only on immunologic and virologic values?

Pezzotti P, d'Arminio Monforte A, Bugarini R, Rezza G, Arici C, Angarano G, Borderi M, Alberici F, Armignacco O, Menichetti F, Prestileo T, Sighinolfi L, Sinicco A, Resta F, Vigevani M, Ippolito G; ICONA Study Group. Italian Cohort of Naïve Antivirals.

Eur J Epidemiol. 2000;16(10):919-26.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk